The faces of personalized medicine: a framework for understanding its meaning and scope.
暂无分享,去创建一个
[1] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[2] R. Ledley,et al. Reasoning foundations of medical diagnosis. , 1991, M.D. computing : computers in medical practice.
[3] A. Issa,et al. Cost effectiveness of gene expression profiling for early stage breast cancer , 2012, Cancer.
[4] Ginny Allain,et al. Personalized medicine. , 2012, MLO: medical laboratory observer.
[5] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[6] G. Lyman,et al. Cost effectiveness of gene expression profiling for early stage breast cancer , 2012, Cancer.
[7] J. Janssen,et al. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. , 2011, Pharmacogenomics.
[8] Peter J Neumann,et al. Personalized medicine: factors influencing reimbursement. , 2010, Health policy.
[9] S. le Cessie,et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.
[10] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[11] M. Manns,et al. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] Ulrich Mansmann,et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Z. Tezak,et al. US FDA and personalized medicine: in vitro diagnostic regulatory perspective. , 2010, Personalized medicine.
[14] W. Gibson. Can personalized medicine survive? , 1971, Canadian family physician Medecin de famille canadien.
[15] R S LEDLEY,et al. Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. , 1959, Science.
[16] Gibson Wm. Can Personalized Medicine Survive , 1971 .
[17] Mark R. Trusheim,et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.
[18] J. Woodcock,et al. The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.